Studies performed at Hadassah Medical Center in Jerusalem on fat mouse and diabetic rat models showed Namodenoson induced weight loss and normalized glucose levels.
The company has filed a patent application through the World Intellectual Property Organization for the use of Namodenoson as an anti-obesity drug.
Topline results from a Phase 2 study in patients with nonalcoholic fatty liver disease (NAFLD), with or without NASH, should be available this quarter.
A Phase 3 trial in certain liver cancer patients should launch soon.
Try Seeking Alpha PREMIUM for unlimited analysis on CANF